よむ、つかう、まなぶ。
【参考資料5】抗微生物薬適正使用の手引き 第三版 別冊 (42 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
別冊
86. Kadri SS, Adjemian J, Lai YL. et al. Difficult-to-Treat Resistance in Gram-negative
Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors,
and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018 Nov;67(12):18031814.
87. Mano Y, Saga T, Ishii Y. et al. Molecular analysis of the integrons of metallo-beta-lactamaseproducing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs
across Japan. BMC Microbiol. 2015 Feb;15:41.
88. Nakayama R, Inoue-Tsuda M, Matsui H, Ito T, Hanaki H. Classification of the metallo betalactamase subtype produced by the carbapenem-resistant Pseudomonas aeruginosa
isolates in Japan. J Infect Chemother. 2022 Feb;28(2):170-175.
89. Uechi K, Tada T, Shimada K. et al. A Modified Carbapenem Inactivation Method, CIMTris, for
Carbapenemase Production in Acinetobacter and Pseudomonas Species. J Clin Microbiol.
2017 Dec;55(12):3405-3410.
90. 西村翔. CRE の治療 (5) J-IDEO Vol.4 No.5. 2020.
91. Pogue JM, Kaye KS, Veve MP. et al. Ceftolozane/Tazobactam vs Polymyxin or
Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas
aeruginosa. Clin Infect Dis. 2020 Jul;71(2):304-310.
92. Motsch J, Murta de Oliveira C, Stus V. et al. RESTORE-IMI 1: A Multicenter, Randomized,
Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus
Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis.
2020 Apr;70(9):1799-1808.
93. Karlowsky JA, Lob SH, Raddatz J. et al. In Vitro Activity of Imipenem/Relebactam and
Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-toTreat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial
Resistance Trends, United States 2015-2017. Clin Infect Dis. 2021 Jun;72(12):2112-2120.
94. 西村翔. 誰も教えてくれないザバクサの使いドコロ J-IDEO Vol.3 No.4. 2019:8295. Karlowsky JA, Lob SH, DeRyke CA. et al. In Vitro Activity of Ceftolozane-Tazobactam,
Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas
aeruginosa Isolates Collected in United States Hospitals According to Results from the
SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022
May;66(5):e0018922.
96. Hart DE, Gallagher JC, Puzniak LA, Hirsch EB, C/T Alliance to deliver Real-world Evidence
(CARE). A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in
Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa
Infections. Open Forum Infect Dis. 2021 Mar;8(3):ofab089.
97. Corbella L, Boan J, San-Juan R. et al. Effectiveness of ceftazidime-avibactam for the
treatment of infections due to Pseudomonas aeruginosa. Int J Antimicrob Agents. 2022
Feb;59(2):106517.
98. Stone GG, Newell P, Gasink LB. et al. Clinical activity of ceftazidime/avibactam against MDR
Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the
ceftazidime/avibactam Phase III clinical trial programme. J Antimicrob Chemother. 2018
Sep;73(9):2519-2523.
42
第三版
別冊
86. Kadri SS, Adjemian J, Lai YL. et al. Difficult-to-Treat Resistance in Gram-negative
Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors,
and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018 Nov;67(12):18031814.
87. Mano Y, Saga T, Ishii Y. et al. Molecular analysis of the integrons of metallo-beta-lactamaseproducing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs
across Japan. BMC Microbiol. 2015 Feb;15:41.
88. Nakayama R, Inoue-Tsuda M, Matsui H, Ito T, Hanaki H. Classification of the metallo betalactamase subtype produced by the carbapenem-resistant Pseudomonas aeruginosa
isolates in Japan. J Infect Chemother. 2022 Feb;28(2):170-175.
89. Uechi K, Tada T, Shimada K. et al. A Modified Carbapenem Inactivation Method, CIMTris, for
Carbapenemase Production in Acinetobacter and Pseudomonas Species. J Clin Microbiol.
2017 Dec;55(12):3405-3410.
90. 西村翔. CRE の治療 (5) J-IDEO Vol.4 No.5. 2020.
91. Pogue JM, Kaye KS, Veve MP. et al. Ceftolozane/Tazobactam vs Polymyxin or
Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas
aeruginosa. Clin Infect Dis. 2020 Jul;71(2):304-310.
92. Motsch J, Murta de Oliveira C, Stus V. et al. RESTORE-IMI 1: A Multicenter, Randomized,
Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus
Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis.
2020 Apr;70(9):1799-1808.
93. Karlowsky JA, Lob SH, Raddatz J. et al. In Vitro Activity of Imipenem/Relebactam and
Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-toTreat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial
Resistance Trends, United States 2015-2017. Clin Infect Dis. 2021 Jun;72(12):2112-2120.
94. 西村翔. 誰も教えてくれないザバクサの使いドコロ J-IDEO Vol.3 No.4. 2019:8295. Karlowsky JA, Lob SH, DeRyke CA. et al. In Vitro Activity of Ceftolozane-Tazobactam,
Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas
aeruginosa Isolates Collected in United States Hospitals According to Results from the
SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022
May;66(5):e0018922.
96. Hart DE, Gallagher JC, Puzniak LA, Hirsch EB, C/T Alliance to deliver Real-world Evidence
(CARE). A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in
Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa
Infections. Open Forum Infect Dis. 2021 Mar;8(3):ofab089.
97. Corbella L, Boan J, San-Juan R. et al. Effectiveness of ceftazidime-avibactam for the
treatment of infections due to Pseudomonas aeruginosa. Int J Antimicrob Agents. 2022
Feb;59(2):106517.
98. Stone GG, Newell P, Gasink LB. et al. Clinical activity of ceftazidime/avibactam against MDR
Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the
ceftazidime/avibactam Phase III clinical trial programme. J Antimicrob Chemother. 2018
Sep;73(9):2519-2523.
42